UCL lecture - 06 February 2017
-
Upload
james-stones-phd -
Category
Documents
-
view
13 -
download
3
Transcript of UCL lecture - 06 February 2017
![Page 1: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/1.jpg)
www.beckgreener.com
|
Dr James Stones6 February 2017
AN INTRODUCTIONTO
INTELLECTUAL PROPERTY
![Page 2: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/2.jpg)
www.beckgreener.com
|An Introduction to Intellectual Property | 6 February 2017 2
Who am I?• BSc Chemistry – Imperial College (1989-1992)
• PhD Chemistry – Imperial College (1992-1996)“[4+2] cycloaddition reactions of conformationally restricted tethered trienes and dienynes”Supervisors - Prof. Donald Craig (IC) & Dr Mark Ford (AgrEvo)
• Joined patent profession in 1996
• Certificate in Intellectual Property (1997)
• European Patent Attorney (2005)
• Chartered Patent Attorney (2006)
• Became a partner at Beck Greener in 2010
![Page 3: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/3.jpg)
www.beckgreener.com
|An Introduction to Intellectual Property | 6 February 2017 3
My Firm• Patent, trade mark & design attorneys• IP litigators
• Based in Holborn (adjacent Gray’s Inn Gardens)
• Established 1867 – 150th anniversary!• Oldest firm of patent attorneys (in continuous existence) in England
• 22 fee earners, incl. 11 partners – unusual model• 55 people in total
![Page 4: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/4.jpg)
www.beckgreener.com
| 4
What are we going to talk about today?PART 1 Introduction to intellectual property (IP)
(45 min)
- Break -
PART 2 Case study
(20 mins)
PART 3 Initiating a pharmaceutical start up
IP aspects to consider
(40 min)
Questions
An Introduction to Intellectual Property | 6 February 2017
![Page 5: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/5.jpg)
www.beckgreener.com
| 5
PART 1
Introduction to Intellectual Property
An Introduction to Intellectual Property | 6 February 2017
![Page 6: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/6.jpg)
www.beckgreener.com
| 6
What is intellectual property?
“…the fruits of mental creativity…”
Some “fruits” are protectable by Intellectual Property Rights (IPRs)
Territorial – country-by-country
Limited duration (except registered trade marks)
PART 1 - An Introduction to Intellectual Property | 6 February 2017
![Page 7: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/7.jpg)
www.beckgreener.com
| 7
Different types of IPR
Patents
Trade marks
Designs
Copyright
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Non-technical
Technical
![Page 8: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/8.jpg)
www.beckgreener.com
| 8
What is a trade mark?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
“badge of origin”
A sign capable of distinguishing goods/services of one source from another
In theory, anything can be a trade mark
To be registrable, must be capable of graphical representation
Words (e.g. NUROFEN) Logos (e.g. )
Shapes (e.g. )
Company name & product names
![Page 9: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/9.jpg)
www.beckgreener.com
| 9
What is a registered design?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Protects the look of a product, including:
• Appearance
• Shape
• Configuration (or arrangement of parts)
• Decoration
Does not protect the way the product works
Legal right to stop others from commercialising products having same orsimilar design - same “overall impression”
Packaging & implants/applicators/devices
![Page 10: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/10.jpg)
www.beckgreener.com
| 10
What is copyright?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Legal right to stop others from copying a work
A "work" may be:an original literary, dramatic, musical & artistic work
a film, sound recording & broadcast
Typographical arrangements (e.g. the layout of a paper or webpage)
Arises automatically - not registered (in UK)
Possibly least relevant to pharmaceuticals – website, packaging, inserts & marketing
![Page 11: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/11.jpg)
www.beckgreener.com
| 11
What is a patent?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
A legal right to stop others from commercialising your invention
“commercialising” = making, using, selling & importing
In return, must disclose invention to the world
![Page 12: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/12.jpg)
www.beckgreener.com
| 12
What is an invention?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
An “invention” is typically a product or a process
To be patentable, an invention must be:
Technical Novel
Not obvious Capable of being made or used in industry
![Page 13: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/13.jpg)
www.beckgreener.com
| 13
Technical Subject Matter
PART 1 - An Introduction to Intellectual Property | 6 February 2017
• Compounds (e.g. APIs, excipients, etc.)
• Compositions/formulations (e.g. coating preparations, dosage forms, etc.)
• Kits (e.g. combination treatments, treatment & applicator, etc.)
• Devices (e.g. implants, applicators, syringes, etc.)
• Packaging
• Methods of manufacture
• Uses/methods of treatment
Technical subject matter in pharmaceuticals includes:
![Page 14: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/14.jpg)
www.beckgreener.com
| 14
Uses/Methods of Treatment
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Therapeutic, surgical and diagnostic methods excluded from patentability in most countries including EPO
Socio-ethical and public health reasons – protect patients
Important exceptions include USA & Australia
• Secondary infringement – supplying means essential to work invention
Cosmetic methods not excluded at EPO
Claim “purpose-limited” product claims?
• Formulation X for use in the treatment of condition Y
![Page 15: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/15.jpg)
www.beckgreener.com
| 15
Novelty
PART 1 - An Introduction to Intellectual Property | 6 February 2017
State of the art is:
• everything made available to the public
• anywhere in the world
• by any means
• before the effective date of the invention (filing/priority date)
Usually prior publications but also presentations and public use
Is the invention new?
Assessed in view of the state of the art
![Page 16: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/16.jpg)
www.beckgreener.com
| 16
Inventive step
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Skilled person is:
• Hypothetical
• Ordinary practitioner – not an expert
• Aware of all relevant art and common general knowledge
• Capable of combining teachings BUT only if art suggests combination
• Has no creative/problem-solving ability
An invention is inventive if not obvious to the skilled person over state of the art
Various approaches – EPO uses “problem/solution” approach
![Page 17: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/17.jpg)
www.beckgreener.com
| 17
Supplementary Protection Certificates
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Compensate for delays in obtaining marketing approval
Does not extend term of patent as such
Protects specific authorised product and any use of the active ingredient in an authorised pharmaceutical product
Enters into force when patent expires and lasts for up to 5 years – paediatric extension?
Requirements
• Valid patent that protects the active ingredient• MA to place active ingredient on market as a pharmaceutical
MA must be the first MA for the active ingredient
![Page 18: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/18.jpg)
www.beckgreener.com
| 18
Know How
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Practical information – usually not patentable
How to implement an invention – best practice
Example - optimisation of a formulation
• Choice/amounts/proportions of excipients• Exact coating thickness• Manufacturing techniques
Can be very valuable
May not be written down
![Page 19: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/19.jpg)
www.beckgreener.com
| 19PART 1 - An Introduction to Intellectual Property | 6 February 2017
![Page 20: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/20.jpg)
www.beckgreener.com
| 20
How to get a patent?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Novelty search by EPOt = ~6 - 12 months
Publicationt = 18 months
Substantive examinationt = ~2 - 5 years
Grantt = ~4 - 5 years
Renewal feesuntil t = 20 years
Devise invention
(Pre-filing novelty search?)
File patent application t = 0
![Page 21: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/21.jpg)
www.beckgreener.com
| 21
Likely costs and timings?
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Prepare & file GB priority application t = 0£3K - £6K
Official search (without review) t = 6 months£400
PCT application (including search) t = 12 months £3K - £4K
PCT national phase (each country) t = 30 months £1K - £5K
Examination (each country)£2K - £6K
Grant (each country) t = 4 to 5 years£500 - £1K
Renewals (most countries annual) until t = 20 years £200 - £800
Budget for 5 countries (US, EP, CA, AU & JP) to grant? £50K - £60K
![Page 22: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/22.jpg)
www.beckgreener.com
| 22
Anatomy of a patent
PART 1 - An Introduction to Intellectual Property | 6 February 2017
Specification – legal document
• DescriptionIntroduction – sets sceneDiscussion of preferred embodimentsExamplesDrawings
• ClaimsDefine scope of protection
• AbstractSearch purposes
![Page 23: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/23.jpg)
www.beckgreener.com
| 23PART 1 - An Introduction to Intellectual Property | 6 February 2017
A claim is a statement that defines the invention, i.e. the “boundaries” of protection
Two types of claim:
Independent claim
• Stands alone
• Essential features only
Dependent claim
• Refers to an independent claim
• Preferred features
• Defines fall back positions
What is a patent claim?
![Page 24: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/24.jpg)
www.beckgreener.com
|
Claims – scope (ringfencing)
Independent Claim 1 Prior art
1Dependent Claim 2
Dependent Claim 3
(not allowable)
Prior art 2
(not allowable)
INVENTION
DISCLAIMED (outside claim scope)
PART 1 - An Introduction to Intellectual Property | 6 February 2017 24
![Page 25: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/25.jpg)
www.beckgreener.com
| 25
PART 2 – Case study
PHLORALStep 1 - Consider an Invention Disclosure
Step 2 - Review prior art identified by inventors
Step 3 - Identify novel features
Step 4 - Identify advantages of invention over art
(15 mins)
An Introduction to Intellectual Property | 6 February 2017
![Page 26: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/26.jpg)
www.beckgreener.com
| 26
Case study - Phloral
PART 2 - An Introduction to Intellectual Property | 6 February 2017
New delayed release coating for site specific drug release in colon
Prednisolone tablets (200 mg; 5 wt % active) coated to 8.3% weight gain with mixture (30:70) of high amylose (70%) starch & enteric polyacrylate (Eudragit S)
Prior art - Lancaster & Wheatley 1989 (D1); US5422121; & US5294448 (D3)
Starch = faecal inoculumStarch control = no faecal matter
![Page 27: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/27.jpg)
www.beckgreener.com
| 27
Case study - Phloral
PART 2 - An Introduction to Intellectual Property | 6 February 2017
Novel features of Phloral
• Combination of starch and Eudragit® S
• Proportion of polysaccharide to film forming polymer?
• Drug?
• Coating thickness?
Advantages of Phloral
• Accelerated release in colonic conditions
• Resistant to pancreatic enzymes (despite presence of amylopectin)
![Page 28: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/28.jpg)
www.beckgreener.com
| 28
Case study - Phloral
PART 2 - An Introduction to Intellectual Property | 6 February 2017
Claim 1 as granted (EP2018159B):
• Not just starch – other plausible polysaccharides
• Not just Eudragit® S – other plausible enteric polymers
• Not limited to drug, proportions or coating thickness (dependent claims)
![Page 29: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/29.jpg)
www.beckgreener.com
| 29
PART 3
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Initiating a pharmaceutical start-up
IP aspects to consider
![Page 30: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/30.jpg)
www.beckgreener.com
| 30
IP Aspects
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Set up company• Form company & register domain name
primary and secondary domain names – block others from using similar names?• Register company name as a trade mark
potentially one of most valuable assets• Set up website
obtain rights to web design from designerif/when updated - keep copies of previous webpages?
Employees• Contracts of employment• Confidentiality
protect all confidential information – not just trade secrets & know how, etc.also marketing, finance, future plans, etc.
• Ownershipassign inventor rights to company
![Page 31: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/31.jpg)
www.beckgreener.com
| 31
IP Aspects
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Outside contractors• Confidentiality
Approach under NDAs or after filing first application – preferably both• Ownership
assign inventor rights to company
Start research• Keep detailed records of research
addition data for post grant proceedingsreproducible experimental protocolsinterference in US
• Third party patents?research exemption apply?
![Page 32: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/32.jpg)
www.beckgreener.com
| 32
IP Aspects
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
IP management• Records & diary system
case status & monitor deadlines• Invention disclosure system
invention disclosure form & system for review• Filing system
prosecution/oppositions/revocations• Portfolio management
maintain commercial focus during prosecution & review entire portfolio regularly• Database
store contracts/assignments/licences/invention disclosures
![Page 33: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/33.jpg)
www.beckgreener.com
| 33
IP Aspects
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Products• Mark with patent (application) number
puts infringer on notice - damages• Register product name as trade mark and domain name
Commercialisation• Freedom to operate
Searches in at least primary countries of interest - reasonable business risk• Infringement opinion
If relevant patents identified, get an opinion from an expert• Work around
If infringement likely, can you work around the patent?• Licence
If no work around, can you get a licence?
![Page 34: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/34.jpg)
www.beckgreener.com
| 34
IP Aspects
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Watches• Patent watches
Keep an eye on competitors and technical fieldMonitor status of potentially relevant cases
• Trade mark watchesKeep an eye on attempts to register the same or similar trade marks
Lifecycle management• Plans for expiry of your patent
SPCs – paediatric extensionsDevelopments – other products in pipeline“Evergreen” inventions not allowed
• IP portfolio management
Approaching potential investors
![Page 35: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/35.jpg)
www.beckgreener.com
| 35
Approaching potential investors
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Potential investors want to know exactly what they are paying for
Investigations referred to as “due diligence”
Generally focuses on three issues:
1. Ownership
2. Enforceability - scope/strength of protection
3. Freedom to operate
![Page 36: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/36.jpg)
www.beckgreener.com
| 36
Ownership
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Decided by national law
In UK, ownership is determined by statute (not contract of employment)
For UK-resident inventors, the inventor is first owner unless:
• employed and invention made during the course of the employee’s normal duties, or during duties specifically assigned to him/her; or
• has special obligation to further interests of employer – typically more senior people (e.g. director)
In these cases, first owner is the employer
Employee inventors & non-employed inventors (e.g. contractors) can assign
![Page 37: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/37.jpg)
www.beckgreener.com
| 37
Enforceability
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Does the IP adequately cover the intended product/process?
Does the IP adequately block generic products?
What disclosures have taken place?
Have novelty searches been carried out?
If so, is there any particularly relevant prior art?
Validity opinions in place?
![Page 38: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/38.jpg)
www.beckgreener.com
| 38
Freedom to operate
PART 3 – Initiating a pharmaceutical start-up | 6 February 2017
Before commercialisation, FTO searches MUST be carried out in each country
Have FTO searches been carried out?
If so, has any potentially relevant third party IP been identified?
Validity opinions in place?
Indemnity/insurance
Not only IP – also supply/distribution agreements
![Page 39: UCL lecture - 06 February 2017](https://reader036.fdocuments.in/reader036/viewer/2022081513/58a76eff1a28ab99238b54f5/html5/thumbnails/39.jpg)
www.beckgreener.com
| 39
Questions
An Introduction to Intellectual Property | 6 February 2017